The Sobi partnership and equity financing have resolved the immediate funding gap flagged in the prior 20-F. Key catalysts to watch: PACIFIC-9 Phase 3 readout for monalizumab in H2 2026, IPH4502 Phase 1 data at ENA 2026 on November 18, and TELLOMAK-3 first patient enrollment in Q1 2027. The $75M ATM facility remains available as additional backstop.
Price Chart
Executive Summary
Innate Pharma reported H1 2026 financial results showing a net loss of €19.6M (improved from €21.3M loss in H1 2025) with revenue of €5.7M. The critical news is the closed Sobi partnership for lacutamab with a $75M upfront payment and a €30M equity financing, extending cash runway to Q1 2028. The prior 20-F flagged a going concern risk, but these post-period events materially address that funding gap, making this filing a significant positive catalyst.
Key Facts
- Closed Sobi partnership for lacutamab with $75M upfront payment, closed September 16, 2026
- €30M equity private placement completed August 18, 2026 (17,647,059 shares at €1.70/share)
- Cash runway extended to end of Q1 2028 (from Q3 2026 per prior 20-F)
- H1 2026 net loss improved to €19.6M from €21.3M in H1 2025
- Revenue increased to €5.7M from €4.9M in H1 2025
- Cash position of €21.4M as of June 30, 2026 (down from €44.8M at Dec 31, 2025)
- PACIFIC-9 Phase 3 readout for monalizumab expected H2 2026
- IPH4502 Phase 1 data to be presented at ENA 2026 on November 18, 2026
- TELLOMAK-3 Phase 3 study for lacutamab initiated, first patient expected Q1 2027
- Shareholders' equity negative at €40.5M as of June 30, 2026
Financial Impact
The Sobi partnership provides $75M upfront plus up to $40M near-term milestones and up to $465M in total milestones plus tiered double-digit royalties. The €30M equity raise combined with the Sobi payment extends cash runway from Q3 2026 to Q1 2028, removing near-term going concern risk.
Risk Factors
- Negative shareholders' equity of €40.5M indicates accumulated losses and potential future financing needs beyond Q1 2028
- PACIFIC-9 Phase 3 readout for monalizumab is binary and could disappoint
- IPH4502 is still early-stage Phase 1 with no approved product yet
- Dilution from the €30M private placement (17.6M new shares) and potential future ATM usage
- Collaboration liabilities of €39.6M related to monalizumab co-financing with AstraZeneca
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-062360 |
| Document: a6kseptember172026.htm | 0001628280-26-062360 |
| Document: 0001628280-26-062360-index-headers.html | 0001628280-26-062360 |
| Document: 0001628280-26-062360-index.html | 0001628280-26-062360 |
| Document: 0001628280-26-062360.txt | 0001628280-26-062360 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.57 | awaiting T+20 | — | $1.46 (−7.01%) |
Oct 20, 2026 6d ago | 6-K | $1.58 | awaiting T+20 | — | $1.46 (−7.48%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.46 (−22.34%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.46 (−32.72%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.46 (−33.03%) |
Aug 10, 2026 11w ago | 6-K | $2.22 $2.05 | ▼ −7.66% | ▼ −6.74% | $1.46 (−34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers